INTRODUCTION
The colony-stimulating factors (CSFs) are a set of glycoproteins responsible for the control of blood-cell production (Dexter, 1984) . The initial purification of two of these proteins, i.e. granulocyte/macrophage (GM)-CSF and macrophage (M)-CSF (Stanley & Heard, 1977 ; also called CSF-1), was achieved by conventional chromatography and polyacrylamide-gel electrophoresis. However, the discovery of several new CSFs, e.g. multi-CSF and granulocyte (G)-CSF (Nicola et al., 1983) , and the availability of h.p.l.c. techniques suitable for the purification and high resolution and recovery of protein mixtures (Nice et al., 1979; Cooke et al., 1983) , has necessitated the development of an improved method for the purification of GM-CSF. More sensitive analytical techniques (Morrisey 1981; Merril et al., 1982) have permitted a better assessment of the purification scheme, so that the protein could be obtained in a form suitable for micro-sequence analysis (Simpson & Nice, 1984) and radiolabelling for receptor studies (Guilbert & Stanley, 1980; .
The observation of a factor in endotoxin serum, which stimulated leukaemic-cell differentiation (Metcalf, 1980; Lotem et al., 1980; , and whicn appeared to be associated with a G-CSF, initiated a search for a suitable source for this protein (Nicola & Metcalf, 1981) . Mouse lung conditioned medium (MLCM) appeared to be the most suitable starting material for the purification of both GM-and G-CSF. This required a change in the initial purification steps for GM-CS , so that both GM-CSF and G-CSF (Nicola et al., 1983) could be recovered in good yield.
The initial steps used to extract the G-CSF did not remove a significant amount of protein from the GM-CSF, but resulted in a high-salt solution, necessitating a different approach to the initial purification steps . This purification scheme concentrates on the GM-CSF glycoprotein, which binds to concanavalin A-Sepharose, as it has been difficult to remove the large amount of contaminating protein from the conditioned medium by precipitation or absorption techniques, without co-precipitating the GM-CSF. However, the combination of conventional chromatography, to decrease the total protein mass, followed by several high-resolution h.p.l.c. steps produced four species of GM-CSF in good yield. The biological properties, the extent of glycosylation of the different forms and the radioiodination of the purified GM-CSFs are described in detail. The specific radioactivity of the radioiodinated derivative was determined by reversephase h.p.l.c. on a microbore column . The 125I-labelled GM-CSF retained full biological activity and appears to be suitable for detailed receptor analysis (Walker & Burgess, 1985) .
MATERIALS AND METHODS Chemicals
All reagents were AnalaR or h.p.l.c. grade unless specifically stated. Buffers were prepared in water obtained from a reverse-osmosis Super Q water polishing system (Millipore). All buffers contained NaN3 (0.02%, w/v) and Tween 20 (0.02%, v/v) unless otherwise stated. Biological assays for GM-CSF activity Samples to be assayed for GM-CSF activity were diluted and filter-sterilized, before assay with C57B1 mouse bone-marrow cells as described previously (Metcalf, 1977) . [Fractions containing toxic buffers such as acetonitrile were always diluted at least 1: 100 before the assay.] Samples containing SDS were treated with a Dowex mixed-bed ion-exchange resin, AG501-X8(D), before sterilization with 0.45 um Millipore filters.
Preparation of mouse lung conditioned medium (Step 1)
Conditioned medium was prepared in the presence of LiCl from the lungs of endotoxin-treated mice (C57BL/6f/J/WEHI strain, 3-4-month-old males and females) as described previously . Initially, the G-CSF was removed by salting out and phenyl-Sepharose chromatography (Nicola et al., 1983) .
Chromatographic procedures
Step 2a: salting-out chromatography. Batches (3 litres) of MLCM were concentrated to 100 ml and exchanged into sodium phosphate buffer (0.1 M, pH 6.0) by using a Hl P0 hollow-fibre cartridge in an Amicon DC2A concentrator. Sepharose CL-6B (Pharmacia; 200 ml) was equilibrated with sodium phosphate buffer (0.1 M; pH 6.0) containing (NH4)2SO4 (1 M), and the packed gel was added to the concentrated MLCM. Then 600 ml of sodium phosphate buffer (0.1 M, pH 6.0) containing (NH4)2SO4 (4 M) was added slowly (50 ml/h) with continuous mixing. This was done with an overhead stirrer, to avoid damage to the Sepharose beads. A considerable portion of the protein precipitates on to the surface of the Sepharose beads. The Sepharose was washed with sodium phosphate buffer (0.1 M; pH 6.0) containing (NH4)2SO4 (2.75 M), on a sintered-glass funnel. The washed Sepharose was poured into a column (2.6 cm x 40 cm), and the proteins were eluted with a linear gradient (600 ml) from 2.75 M-(NH4)2SO4 in buffer to buffer alone at a flow rate of 25 ml/h, 4.5 ml fractions being collected. The GM-CSF was eluted between 2.5 Mand 1.8 M-(NH4)2SO4 (Nicola et al., 1983) , together with most of the protein, but substantially free of G-CSF (Nicola et al., 1983) . To avoid G-CSF contamination, those fractions that contained both GM-CSF and G-CSF were pooled with the G-CSF fractions and further purified by phenyl-Sepharose chromatography (Nicola et al., 1983) , i.e.
Step 2b below. The fractions containing GM-CSF but not G-CSF were pooled (approximately 90 ml) for the next purification procedure, concanavalin A-Sepharose chromatography.
Step 2b: phenyl-Sepharose CL-6B chromatography. The fractions from the salting-out chromatography which still contained G-CSF were pooled (approx. 110 ml) and applied directly to a column (2.6 cm x 20 cm) of phenyl-Sepharose CL-6B (Pharmacia) previously equilibrated with sodium phosphate buffer (0.1 M; pH 6.0) containing (NH4)2SO4 (1 M). The column was washed with 50 ml of this equilibrated buffer, and then the proteins were eluted with a linear gradient (200 ml), starting with the equilibration buffer and finishing with water containing NaN3 (0.02%) and Tween 20 (0.02%). The GM-CSF was eluted from the phenyl-Sepharose between 0.8 M-and 0.5 M-(NH4)2SO4 and contained no G-CSF. The G-CSF was eluted from the phenyl-Sepharose with a second linear gradient (200 ml) from water to ethylene glycol/water (3:2, v/v) containing NaN3 (0.02%) and Tween 20 (0.02%) (Nicola et al., 1983) . The fractions containing GM-CSF were pooled (approx. 50 ml) and combined with the GM-CSF pool from the salting-out chromatography.
Step 3: concanavalin A-Sepharose chromatography. The fractions containing GM-CSF from six salting-out columns and six phenyl-Sepharose columns were pooled, adjusted to pH 5.0 and made 0.2 M with sodium acetate buffer (1 M stock solution) and 1 mM-MgCl2 . Affinity chromatography on concanavalin A-Sepharose was performed as described previously , except that 1 ml of packed concanavalin A-Sepharose (Pharmacia) was used for each 50 mg of total protein, to absorb the glycoproteins. After loading the sample,. the column was washed with 2 column vol. ofbuffer before elution ofthe glycoproteins with a mixture of a-methyl glucopyranoside (0.05 M) and cc-methyl mannopyranoside (0.05 M) at a flow rate of 20 ml/h. Retained GM-CSF was recovered in a volume of approx. 80 ml.
Step 4: gel Mtration on Ultrogel AcA54. The pool of GM-CSF that bound to the concanavalin A-Sepharose column was concentrated to 10 ml over anAmicon PM-10 membrane and applied to a column (2.4 cm x 180 cm) of Ultrogel AcA54 equilibrated with Tris/HCl (20 mM; pH 7.4). The flow rate was maintained at 30 ml/h, and 10 ml fractions were collected. The fractions containing GM-CSF were pooled for the final h.p.l.c. (Fig. 1) . H.p.l.c. separations Preparative separations were performed on a Beckman model 324-40 h.p.l.c. apparatus fitted with a 2 ml injection loop. Large-volume samples were loaded either by multiple injection (less than 10 ml) or by pumping directly through the primary pump (greater than 10 ml). Detection was by sequential u.v. adsorption at 280, 215 or 210 nm (LDC Spectromonitor III) and endogenous fluorescence (Kratos FS950; 214 nm excitation; 340 nm emission). Fractions were recovered with a pharmacia FRAC100 collector controlled by the Beckman 324-40 microprocessor. Polyethylene glycol (0.005 %, w/v) or Tween 20 (0.02%) was added to recovered fractions to minimize loss of protein by non-specific adsorption to the polypropylene collection tubes. Chromatographic conditions for the specific separations are listed below. All separations were achieved at ambient temperature.
Step 5: reversed-phase chromatography (RP-h.p.l.c [0-50% (v/v) , increasing at 1 % /min) at a flow rate of 1 ml/min (Fig. 2 ).
Step 6: anion-exchange h.p.l.c. The pooled fractions from the reversed-phase h.p.l.c. in the presence of HFBA were pooled (5 ml), diluted 10:1 with Tris/HCl (20 mm, pH 8.0) and loaded directly on to a Pharmacia Mono Q column (Burgess et al., 1983 ) equilibrated with the Tris/HCI buffer. After loading the sample, the proteins were eluted at a flow rate of 1 ml/min with a discontinuous salt (NaCl) gradient in the buffer: 0-0.1 M in 5 min, followed by 0.1-0.15 M in 30 min (Fig. 3 ).
Step 7: Reversed-phase h.p.l.c. with NaCI and acetonitrile. The presence ofHFBA selectively alters the elution characteristics of many proteins by ion-pairing (Bennett et al., 1980; Burgess et al., 1982) , but the efficiency of the chromatography is often inferior to separations in the presence of high concentrations of NaCl (Nice et al., 1979; Cooke et al., 1983) . The final step in our purification procedure used the Beckman RPSC column (see Step 5) equilibrated with water containing NaCl (0.9%) and adjusted to pH 2.1 with HCI. The proteins were eluted with a shallow gradient (see Fig. 6 ) of acetonitrile at a flow rate of 0.5 ml/min. 
Analysis of different molecular forms of purified GM-CSF
Small samples of the biologically active fractions from the reversed-phase h.p.l.c. in the presence of NaCl were analysed by size-exclusion chromatography on a TSK3000 SW column (30 cm x 7.5 mm internal diam.) equilibrated with ammonium acetate (50 mM; pH 6.5) containing Tween 20 (0.02%). The column was developed at 0.25 ml/min and fractions were collected every I min. The column was calibrated with a set of Mr standards, and the apparent Mr of each GM-CSF was estimated by extrapolation (Gough & Gough, 1983) . The Mr values of the forms were also determined by SDS/polyacrylamidegel electrophoresis on 12% -polyacrylamide gels (Laemmli, 1970) . The protein was detected on the gels by silver staining (Morrisey, 1981) , and the biological activity was determined as described previously Metcalf, 1977) .
Preparation of 1251-labelled GM-CSF
Purified GM-CSF (from Step 6) was radioiodinated by the method of Tejedor & Ballesta (1982) . A sample of GM-CSF containing approx. 1 ,ug was concentrated to 60 ,1 with a Speedi-vac rotary evaporator. The solution was made up to 0.125 mm in KI and buffered with 10 1 of sodium borate (0.2 M; pH 8.4). Then 1 mCi (10 ,ul) of carrier-free 1251-(Amersham International, Amersham, Bucks., U.K.) was added to the reaction mixture, which was then exposed to chlorine gas for 30 min. The filter pad containing the NaCl and chloramine-T was replaced at 10 min and 20 min. Free iodide was removed by exchanging the 1251-labelled GM-CSF into phosphatebuffered saline (0.14 M-NaCl/0.02 M-sodium phosphate, pH 7.4) on a Sephadex G-25 column (Pharmacia, PD-10 column). The 125I-labelled GM-CSF was analysed by SDS/polyacrylamide-gel electrophoresis (Laemmli, 1970) , isoelectric focusing in agarose gels (Burgess et al., 1983) , microbore reversed-phase h.p.l.c. and the TSK3000 SW column. Specific radioactivity of 1251-labelled GM-CSF This was determined by microbore reversed-phase h.p.l.c. as described previously . A Hewlett-Packard model 1090 high-performance liquid chromatograph fitted with a model 1040 diode-array detector and a 250,ul autoinjection syringe was used. Separation was obtained on a Brownlee RPP 'guard' column (3 cm x 2.1 mm internal diam.; 30 nm pore-size silica, C8 bonded phase) at 45 'C and a flow rate of 100 #I/min with a linearly increasing gradient
(1 % /minute) between 0.9 % NaCl (pH 2.1) and acetonitrile. Detection was at 210 nm, with a reference wavelength of 320 nm. A 150,u sample of the radioiodinated GM-CSF preparation was injected. Fractions were collected manually at 2 min intervals (allowing for the 50 ,u dead volume between the detector flow cell and the outlet port), and the associated radioactivity was determined with a Packard Autogamma 500C counter with an automatic 1251 efficiency-determination programme. The apparent mass of GM-CSF was determined by comparison of the observed peak area with the peak areas of a set of bovine serum albumin standards.
Glycosidase treatment of 1251-labelled GM-CSF '251-labelled GM-CSF (approx. 1 uCi in 5 ml) was mixed with 5 ,tl of sodium acetate buffer [50 mM; pH 5.0; containing Tween 20 (0.02% ) and mercaptoethanol (2%, v/v)] and 0.5 ul of endoglycosidase F (New England Nuclear), endoglycosidase D (Seikagaku, Japan), endoglycosidase H (New England Nuclear) or neuraminidase (Worthington). Each incubation contained 2 munits of enzyme. The incubations were allowed to proceed for 1 h, 2 h or 22 h before the samples were mixed with either isoelectric-focusing sample buffer (O'Farrell, 1975) or SDS/polyacrylamide-gel-electrophoresis sample buffer (O'Farrell, 1975) for analysis.
Protein assays
The total protein estimates for the first four purification procedures were made by the method of Lowry et al. (1951) , but after that stage there was insufficient protein to obtain an accurate estimate by that procedure. Thus the protein content of fractions eluted from the h.p.l.c. columns was estimated by comparison of the A215 with that of a bovine serum albumin standard. Although this method is unlikely to yield the absolute value for GM-CSF protein, it does allow a direct comparison of the biological and specific activity of different preparations.
RESULTS AND DISCUSSION
The discovery of colony-stimulating factor, G-CSF, in endotoxin serum and subsequently in MLCM (Nicola & Metcalf, 1981) meant that this conditioned medium was a valuable source for at least two distinct haemopoietic regulators, GM-CSF and GM-CSF. The initial purification scheme for the isolation of GM-CSF from MLCM was not appropriate for the preparation of G-CSF at the Vol. 235 Table 1 . Purification and properties of granulocyte/macrophage colony-stimulating factor from mouse lung conditioned medium The procedure started with 18 litres of MLCM . Steps 2a and 2b were performed with 3-litre batches of MLCM, but the quantities calculated represent an 18-litre batch.
Step 3 was performed on the active fractions pooled from six step-2 purifications. same time. Indeed, to allow larger volumes of MLCM to be used for the purification of GM-CSF, an (NH4)2SO4 (50-80%) precipitation step was introduced. However, although this precipitated the GM-CSF, the G-CSF did not precipitate quantitatively. Also, the original procedure for obtaining GM-CSF involved a final preparative gel-electrophoresis procedure, and contamination with gel-related artefacts prevented the efficient radioiodination and analysis of the purified molecule. The development of h.p.l.c. procedures for the purification of low-abundance hydrophobic proteins (Nice et al., 1979; Cooke et al., 1983) such as GM-CSF has led to the development ofa new purificatioriprocedure which yields several forms of GM-CSF, which are suitable as biological reagents for analysis and receptor studies.
Purification of GM-CSF from mouse lung conditioned medium
The preparation of MLCM with optimal contents of GM-CSF and minimal amounts of mouse serum is described in the original purification procedure . The salting-out chromatography using Sepharose CL-6B and (NH4)2S04 has been described in detail (Nicola et al., 1983) and is essentially the same as the published procedure. All of the GM-CSF activity free of G-CSF was kept, and the remainder of the GM-CSF activity (which is associated with all of the G-CSF) was recovered from the early-eluted material from the phenyl-Sepharose CL-4B column. The proportion of GM-CSF free of G-CSF was often greater than 80%, but sometimes more than 30% ofthe total GM-CSF from the salting-out column was still associated with G-CSF. All of this GM-CSF was recovered from the phenylSepharose CL-4B column and pooled with the salting-out fraction. Although these two procedures considerably decreased the amount of protein associated with the GM-CSF, there was some loss of biological activity (Table 1) . However, the GM-CSF and G-CSF molecules were completely separated.
A most effective procedure for removing most of the protein from the Step-2 material (Table 1) the glycoprotein fraction allowed the removal of not only 95% of the contaminating proteins, but in particular the albumin, which often makes the final purification of the CSFs particularly difficult. The proportion of GM-CSF binding to concanavalin A-Sepharose varied between preparations (from 40 to 60% ), but in most preparations only half of the GM-CSF bound to concanavalin A-Sepharose appeared to be eluted with a-methyl mannopyranoside and ax-methyl glucopyranoside. Despite this relatively low recovery, the 5-fold increase in purity of the GM-CSF, coupled with the specific removal of the albumin, justifies its inclusion in the purification scheme. (Fig. 1), but, in agreement with the previous results with Ultrogel AcA44 , the GM-CSF was eluted with an apparent Mr of 29000 (Kav = 0.28). The recovery of the GM-CSF was quantitative, and the further 10-fold purification decreased the protein content sufficiently to allow a high-resolution reversed-phase h.p.l.c. procedure. Although phosphate-buffered saline was used for the gel filtration, it was still possible directly to trace-enrich ) the GM-CSF from the pooled active fractions (80 ml) directly on to the Ultrapore RPSC C3. It is possible to perform the Ultrogel AcA54 purification with Tris/HCl (pH 7.0,20 mM) with equal efficiency. This allows the GM-CSF to be recovered and eluted from calcium phosphate gel Keilin & Hartree, 1938 ) before h.p.l.c. Although we have not had sufficient experience with this procedure to determine the effect of this extra procedure on overall recovery, it has been useful for the further purification of the GM-CSF which fails to bind to concanavalin A-Sepharose.
Our initial reversed-phase h.p.l.c. was performed on a short-alkyl-chain (C3) large-pore (30 nm) column packing to improve the recovery of the GM-CSF, even at high protein loads. Several solvents (e.g. propan-l-ol, propan-2-ol and acetonitrile) were tested, but the acetonitrile gradient provided the best protein resolution without compromising GM-CSF recovery. This first reversedphase h.p.l.c. step was performed with HFBA as an ion-pairing agent. In addition, the poor u.v.-absorption characteristics of this solvent suggested use at a relatively early stage in the h.p.l.c. purification, when there was still sufficient protein present to monitor at 280 nm. The GM-CSF was eluted from the column between 42 and 47 min, slightly behind the major protein peak (Fig. 2) . (Fig. 2) The column was equilibrated with Tris/HCl (20 mM; pH 8), and the reversed-phase h.p.l.c. pool was diluted 10:1 with this buffer and loaded directly on to the column. After re-equilibration of the column, the proteins were eluted with a discontinuous NaCl gradient: initially the NaCl concentration (----) was increased to 0. ). The GM-CSF content of each fraction was measured (E2l) on diluted (1:1000) samples from each fraction (1 ml) by using the standard bone-marrow assay.
Vol. 235 The sample (20 ,l) was mixed with an equal volume of SDS sample buffer and 20 1ld of the mixture loaded into each of two lanes for electrophoresis. Half of the gel was silver stained (left panel) and the other lane was sliced into 2 mm segments, each of which was crushed into 1 ml of phosphate-buffered saline containing bovine serum albumin (10 mg/ml), and the proteins were eluted overnight.
A mixed-bed ion-exchange resin was added to each eluate for 30 min before sterilization by filtration. These eluates were assayed at several dilutions for GM-CSF by the standard soft-agar bone-marrowcolony assay (Metcalf, 1977) , and the results for each fraction are presented graphically in the middle panel of the Figure. The apparent Mr values were estimated by extrapolation from a standard curve obtained by using mobility of the Pharmacia low-Mr markers (right panel: bovine serum albumin, 68 000; ovalbumin, 43 000; carbonic anhydrase, 30000; soya-bean trypsin inhibitor, 20000.
Most of the proteins were well resolved, and were eluted with high efficiency. Although the GM-CSF was broader than the other protein bands (perhaps reflecting some heterogeneity in the biologically active protein), the recovery was greater than 80%, and more than 95% of the contaminating proteins were removed by this procedure.
Although there was some charge heterogeneity associated with GM-CSF, the earlier purification procedure indicated that ion-exchange chromatography on DEAE-Sephadex was an effective purification procedure . Thus the pooled fractions from the reversed-phase h.p.l.c. were loaded directly on to a Pharmacia Mono Q column, after dilution of the HFBA and adjustment of pH, and the proteins were fractionated with a shallow NaCl gradient (Fig. 3) . Most of the protein was only weakly retained by this packing and was eluted well before the GM-CSF, which was eluted underneath a broad 'heterogeneous' protein peak (Fig. 3) . Recovery ofbiological activity from this step was only 68%, but again there was an effective decrease in contaminating protein, and a significant purification of the GM-CSF was achieved. All of the fractions eluted between 0.11 M-and 0.13 M-NaCl (i.e. 15-20 min) were pooled, and the protein heterogeneity and GM-CSF activity were analysed by SDS/polyacrylamide (10% )-gel electrophoresis. Halfofthe gel was silver stained to detect the proteins; the other halfwas sliced into 2 mm segments and the GM-CSF extracted for assay. Only three proteins were detected by silver staining (Fig. 4) : two of the proteins were associated with GM-CSF activity (at Mr 23000 and 21000). Indeed, the specific activity of these two CSFs appeared to be identical, and morphological analysis of the bone-marrow colonies (Metcalf, 1977) indicated that both species yielded the same preparations of pure granulocytic (42% ), mixed granulocyte/ macrophage(29% ) and pure macrophage colonies (27%).
There was no biological activity associated with the other protein (Mr 39000).
Several procedures were used in an attempt to separate the 'two' forms of GM-CSF and to remove the contaminating Mr-39000 protein. Analysis of the GM-CSF eluted from the Pharmacia Mono Q column by size-exclusion chromatography on a TSK3000 SW column (Fig. 5) yielded a single peak of protein and biological activity at an apparent Mr of 29000 (in agreement with the results from the Ultrogel AcA54 column; Fig. 1 ). This was somewhat surprising, as we would have expected to separate the Mr-39 000 protein from the GM-CSF. Thus the usefulness of these h.p.l.c. (Fig. 3) , on a Beckman TSK3000 SW column
The protein was monitored by the A215 ( ) and the GM-CSF (E3) by assay after dilution (1:100) by the softagar bone-marrow-colony assay (Metcalf, 1977) . The column was calibrated with bovine serum albumin ('68K'), ovalbumin ('43K') and a-lactalbumin ('15K') as
Mr markers. The pooled fractions from the Pharmacia anion-exchange h.p.l.c. Mono Q column (Fig. 3) were pumped on to the Beckman Ultrosphere RPSC (C3, 30 nm), column which had been equilibrated at pH 2.1 with NaCl (0.9%). Elution of proteins from the column was performed with a discontinuous gradient ofacetonitrile (--, l-ower panel). The proteins eluted from the column ( , lower panel) were monitored at 210 nm. The GM-CSF content ofeach fraction (L, upper panel) was measured by titration after dilution (1: 1000) and sterilization, by using the semi-solid bone-marrow-colony assay (Metcalf, 1977) . The two major peaks of protein, after 28 and 35 min corresponded to the GM-CSF.
gel-filtration columns for high-resolution analysis is somewhat limited for this particular application, since the electrophoresis results indicated that at least three different proteins were present across the apparently homogeneous protein peak (Fig. 5) .
Final purification and separation of multiple forms of GM-CSF was achieved by returning to the Ultrapore RPSC (C3) column, but replacing the HFBA by NaCl (0.9%, adjusted to pH 2.1 with HCl) and employing a shallow gradient (Fig. 6) . Two major peaks of protein (with a leading shoulder on the first peak) were detected. The biological activity was coincident with these two peaks ofprotein. SDS/polyacrylamide (10% )-gel electrophoresis was used to analyse the proteins in the active fractions (Fig. 7) . The two major peaks of biological activity (Fig. 6 ) contained proteins with of apparent Mr 23 000 and 21 000 (Fig. 7) . Thus four species of GM-CSF (A, B, C, D) were identified and purified by this procedure. The contaminating protein (Mr 39000) was not eluted from the Ultrapore RPSC column in the presence of NaCl, and was only washed from the column when the column was cleaned with HFBA (0.2%). The overall recovery of GM-CSF from the final procedure was essentially quantitative and represented approx. 12% of the initial GM-CSF present in the MLCM. Only 6-12 ,ug of each species was produced from the 18 litres of starting MLCM, and this represented a purification of 105-fold for each. The biological properties of all four species were identical, each being capable of stimulating granulocytic, granulocyte/macrophage and pure macrophage colonies in similar proportions to the Stage-6 GM-CSF. [N.B. each of the silver-stained protein bands at Mr 23000 and 21000 detected in the Stage-6 material Vol. 235 (Fig. 4) must consist of two different GM-CSF molecules, which can be separated subsequently on the Ultrapore RPSC (C3) column in the presence of NaCl (Fig. 6 ).] Radioiodination of GM-CSF The GM-CSF purified previously from MLCM was eluted from a preparative polyacrylamide gel and contained buffer ions, detergent and other impurities from the polyacrylamide, which prevented its detailed analysis and radiolabelling. However, in contrast with the M-CSF molecule (Stanley & Heard, 1977; Guilbert & Stanley, 1980) , most methods of radiolabelling significantly decreased the biological activity of mouse GM-CSF . This problem was overcome for G-CSF by using a gas-phase iodination procedure (Tejedor & Ballasta, 1982) , which not only yielded a fully biologically active G-CSF but also attached more than two atoms of 1251 to each molecule of G-CSF. By a similar method 1251 was incorporated into 1,ug of GM-CSF sub-species B (Fig. 7) (all GM-CSF sub-species recovered from the Ultrosphere RPSC column could be iodinated to a similar extent). When 1 mCi of 1251 was used in the iodination reaction, almost 300 ,uCi was incorporated into high-Mr material. Further purification of the labelled protein on CM-Sephadex yielded 1251-labelled GM-CSF (essentially free of 1251-and other low-Mr 1251-labelled contaminants) with a specific radioactivity of 3 x 106-5 x 106 d.p.m./pmol. The specific radioactivity was determined quantitatively by using a microbore column (Fig. 8) , which we have previously shown to be capable of quantifying less than 5 ng of epidermal growth factor . Approx. 10% of the 1251-labelled (Walker & Burgess, 1985) . Glycosidase treatment of 1251-labelied GM-CSF The 125I-labelled GM-CSF was initially analysed by isoelectrofocusing on an agarose gel, and the results were compared with the distribution of biological activity of partially purified (Stage 2; ) MLCM GM-CSF (Fig. 9) . The biological activity of partially purified GM-CSF focused between pH 5.2 and pH 4.2 (Fig. 9, broken line) . The untreated 125I-labelled GM-CSF also focused between pH 4.4 and pH 5.4, indicating that the purification procedure and subsequent radioiodination had not significantly altered the charge distribution of the GM-CSF. Both the GM-CSF biological activity and 1251-labelled GM-CSF focused as distinct charge species, corresponding to discrete charge differences [e.g. sialic acid heterogeneity (Ayasawa et al., 1979; Nicola et al., 1979; Bazill et al., 1983) ]. On treatment of the 125I-labelled GM-CSF and a partially purified GM-CSF preparation with neuraminidase, both the 1251-GM-CSF and biological-activity profiles shifted to a higher pH. The neuraminidase-treated 1251-GM-CSF focused sharply (between pH 5.2 and pH 5.4; Fig. 9 ) and corresponds to the biological activity of the neuraminidase-treated GM-CSF, which focussed between pH 5.2 and pH 5.5 (continuous line, Fig. 9) .
The 125I-GM-CSF was analysed further by SDS/ polyacrylamide-gel electrophoresis (Fig. 10) , GM-CSF, ---, blank) and the 1251 by scintillation counting (lower panel). The protein was eluted from the column with a linearly increasing gradient of acetonitrile (1% /min) at a flow rate of 100 ,u/min. Fractions were collected at 2 min intervals. The apparent mass of 125I-labelled GM-CSF was determined by comparison with the peak area for the A210 of standard amounts of bovine serum albumin. .,**djjft ;i remove carbohydrate from the 1251-labelled GM-CSF, but neuraminidase and endoglycosidase F both removed carbohydrate side chains. The neuraminidase decreased the Mr of 1251I-labelled GM-CSF to 19000, and the endoglycosidase F to 16500 (Fig. 10) . Treating the 1251-labelled GM-CSF with both enzymes did not lower the Mr of the GM-CSF any further. Treatment of the Mr-23000 1251-labelled GM-CSF C sub-species (Figs 6 and 7) yielded identical results (i.e. this sub-species yielded one of Mr 19000 after neuraminidase treatment and 16500 after treatment with endoglycosidase F). Interestingly, the lowest Mr generated for the 125I-labelled GM-CSF molecule after glycosidase treatment is identical with the lowest-Mr subunit reported for glycosidase-treated M-CSF (also called CSF-1) (Das & Stanley, 1982) .
The single Mr species (16500) after endoglycosidase treatment suggests that all of the sub-species share a polypeptide chain of the same length; however, the reason for the different elution positions on reversed-phase h.p.l.c. may be modification other than glycosylation. This is in agreement with the analysis of the gene for mouse GM-CSF, which indicates that there is only a single copy (Gough et al., 1984) . The apparent Mr of the glycosidase-treated GM-CSF is slightly larger than the size predicted from the cDNA sequence reported by- Gough et al. (1984) . This difference may be due to residual carbohydrate, anomalous electrophoretic behaviour or an uncleaved precursor sequence at the N-terminus. Although the N-terminal sequence of asialo-(mouse GM-CSF) has been determined (Sparrow et al., 1984) , attempts to sequence the N-terminus of the untreated GM-CSF purified in this study yielded only the first four amino acids, Ala-Pro-Thr-Arg (Table 2) . These four residues correspond to a precursor segment Fig. 9 . Isoelectric-focusing analysis of boh untreated and neuraminidase-treated 12514labelled GM-CSF and partially purified GM-CSF Partially purified GM-CSF was subjected to isoelectric focusing (with Pharmalytes, pH 4.5-6) on a polyacrylamide gel, before (----) and after (0O O) treatment with neuraminidase. After focusing, the pH of the gel was recorded with a surface electrode and the gel was sliced into equal segments. The GM-CSF was eluted from the crushed gel and the activity determined by the standard bonemarrow-colony assay. Table 2 . Automated Edman degradation of GM-CSF from MLCM Automated amino acid sequence analysis was performed with an Applied Biosystems sequencer (model 470A), and amino acid phenylthiohydantoins was analysed by h.p.l.c. by the procedure described elsewhere (Simpson et al., 1985) . Samples (67%) from each cycle were analysed by h.p.l.c. and the yields of amino acid phenylthiohydantoins were normalized to 100% injection. predicted by the cDNA clone for mouse GM-CSF from a T-lymphocyte cell line (Gough et al., 1984) . This segment starts six amino acids before the N-terminus determined for the asialo-GM-CSF (Sparrow et al., 1985) , suggesting that the neuraminidase treatment may have modified the N-terminus of a small proportion of the asialo-GM-CSF, allowing an internal fragment to be sequenced. Analysis ofthe 125I-labelled GM-CSF indicated that we
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were able to attach 2-3 atoms of 1251 to the GM-CSF molecule without affectingits biological activity. Although this is considerably less than the 4-6 atoms incorporated into M-CSF (CS-1; Guilbert & Stanley, 1980) , this derivative has been suitable for the detection and analysis of mouse GM-CSF receptors (Walker & Burgess, 1985) .
